(Q22252232)

PubMed

PubMed publication ID

7 February 2023

Yong Shen

2

Yong

Shen

1 reference

PubMed

PubMed publication ID

24998784

7 February 2023

Rena Li

series ordinal

3

author given names

Rena

author last names

Li

1 reference

PubMed

PubMed publication ID

24998784

Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease.

7 February 2023

language of work or name

English

0 references

publication date

November 2014

0 references

published in

Drug Discovery Today

0 references

volume

19

0 references

issue

11

0 references

page(s)

1822-1827

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Evidence that Aβ42 is the real culprit in alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Neurological adverse events associated with anti-tumor necrosis factor α treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

1 reference

7 January 2021

Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Pentoxifylline attenuates TNF-α protein levels and brain edema following temporary focal cerebral ischemia in rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118).

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Extended results of the Alzheimer's disease anti-inflammatory prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

A cellular model of inflammation for identifying TNF-alpha synthesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Tumor necrosis factor-α−308A/G polymorphism is associated with age at onset of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Distinct destructive signal pathways of neuronal death in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Tumor necrosis factor A and MHC class I chain related gene A (MIC-A) polymorphisms in Swedish patients with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Woodchuck lymphotoxin-alpha, -beta and tumor necrosis factor genes: structure, characterization and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Toxicity and Teratogenicity of Optical Isomers of Thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

An endotoxin-induced serum factor that causes necrosis of tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Extensive genetic polymorphism in the human tumor necrosis factor region and relation to extended HLA haplotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

The HLA class III subregion is responsible for an increased breast cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Cognitive improvement with intrathecal administration of infliximab in a woman with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Cytokines and immunity to viral infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Control of synaptic strength by glial TNFalpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Alzheimer's disease: perspectives for the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

A second component of HLA-linked susceptibility to type 1 diabetes maps to class I region

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Cell death after spinal cord injury is exacerbated by rapid TNF alpha-induced trafficking of GluR2-lacking AMPARs to the plasma membrane

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Etanercept: a review of its use in the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Non-class II HLA gene associated with type 1 diabetes maps to the 240-kb region near HLA-B

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Thalidomide attenuates learning and memory deficits induced by intracerebroventricular administration of streptozotocin in rats.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Inhibition of the nuclear factor-kappaB activation with pyrrolidine dithiocarbamate attenuating inflammation and oxidative stress after experimental spinal cord trauma in rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Macro- and microrheological parameters of blood in patients with cerebral and peripheral atherosclerosis: the molecular change mechanisms after pentoxifylline treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021

TNF-alpha is a positive regulatory factor for human Vgamma2 Vdelta2 T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.DRUDIS.2014.06.029

7 January 2021